𝔖 Bobbio Scriptorium

✦ LIBER ✦

ECF vs FELV: similar overall survival in biliary cancer

Book ID: 120854061
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2005
Weight: 138 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200514970-00042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III study of 5FU, etoposide and le

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

✍ Rao, S; Cunningham, D; Hawkins, R E; Hill, M E; Smith, D; Daniel, F; Ross, P J; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 94 KB

44 Phase III trial comparing epirubicin,

44 Phase III trial comparing epirubicin, cisplatin and 5-FU (ECF) versus 5FU, etoposide and leucovorin (FELV) in previously untreated patients with advanced biliary cancer

✍ S. Rao; D. Cunningham; R. Hawkins; M.E. Hill; D. Smith; F. Daniel; P.J. Ross; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Overall survival benefit for weekly vs.

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

✍ Davide Mauri; Konstantinos Kamposioras; Lamprini Tsali; Magdalini Bristianou; An 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 257 KB

After lumpectomy, overall survival is si

After lumpectomy, overall survival is similar with tamoxifen alone compared with tamoxifen plus radiotherapy in elderly women with early stage breast cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Final overall survival results of phase

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

✍ Wagner, U; Marth, C; Largillier, R; Kaern, J; Brown, C; Heywood, M; Bonaventura, 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 242 KB

Androgen suppression therapy, in combina

Androgen suppression therapy, in combination with radiotherapy prolongs overall survival in men with clinically localised prostate cancer: Abstracted from: D’Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer. A randomized controlled trial. JAMA 2004;292:821–27.

✍ Juanita Crook 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 90 KB